$212.56
0.21%
NYSE, Sep 05, 10:10 pm CET
ISIN
US00287Y1091
Symbol
ABBV

AbbVie Stock price

$212.56
+14.01 7.06% 1M
+1.02 0.48% 6M
+34.86 19.62% YTD
+19.70 10.21% 1Y
+76.28 55.97% 3Y
+120.69 131.37% 5Y
+152.79 255.63% 10Y
+177.56 507.31% 20Y
NYSE, Closing price Fri, Sep 05 2025
-0.44 0.21%
ISIN
US00287Y1091
Symbol
ABBV
Industry

Key metrics

Basic
Market capitalization
$375.5b
Enterprise Value
$439.5b
Net debt
$64.0b
Cash
$6.5b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
101.2 | 17.3
P/S
6.4 | 6.1
EV/Sales
7.5 | 7.1
EV/FCF
24.1
P/B
negative
Dividends
DPS
$6.29
Yield 1Y | 5Y
3.0% | 4.2%
Growth 1Y | 5Y
5.0% | 7.5%
Payout 1Y | 3Y
263.2% | 153.2%
Increased
13 Years
Financials (TTM | estimate)
Revenue
$58.3b | $61.9b
EBITDA
$26.5b | $28.8b
EBIT
$18.2b | $28.0b
Net Income
$3.7b | $21.7b
Free Cash Flow
$18.2b
Growth (TTM | estimate)
Revenue
6.1% | 9.9%
EBITDA
8.0% | 15.6%
EBIT
13.8% | 70.0%
Net Income
-29.7% | 411.5%
Free Cash Flow
2.6%
Margin (TTM | estimate)
Gross
70.9%
EBITDA
45.5% | 46.5%
EBIT
31.3%
Net
6.4% | 35.0%
Free Cash Flow
31.3%
Financial Health
Equity Ratio
2.5%
Return on Equity
127.5%
ROCE
18.7%
ROIC
-
Debt/Equity
-385.1
More
EPS
$2.1
FCF per Share
$10.3
Short interest
1.0%
Employees
55k
Rev per Employee
$1.0m
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

37 Analysts have issued a AbbVie forecast:

26x Buy
70%
11x Hold
30%

Analyst Opinions

37 Analysts have issued a AbbVie forecast:

Buy
70%
Hold
30%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
58,328 58,328
6% 6%
100%
- Direct Costs 16,956 16,956
8% 8%
29%
41,372 41,372
13% 13%
71%
- Selling and Administrative Expenses 14,562 14,562
11% 11%
25%
- Research and Development Expense 8,602 8,602
14% 14%
15%
26,509 26,509
8% 8%
45%
- Depreciation and Amortization 8,270 8,270
3% 3%
14%
EBIT (Operating Income) EBIT 18,239 18,239
14% 14%
31%
Net Profit 3,723 3,723
30% 30%
6%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Positive
The Motley Fool
about 2 hours ago
With patent-protected market exclusivity for their products, pharmaceutical companies reliably produce profits that they aren't shy about distributing to shareholders. In an industry already known for relatively strong dividend payout raises, AbbVie (ABBV -0.31%) stands out with a quarterly payment that has soared 221.6% over the past decade.
Positive
The Motley Fool
one day ago
When you're highly confident about your cards in the game of blackjack, you double down. This means that you double your initial bet in exchange for receiving only one additional card.
Neutral
The Motley Fool
2 days ago
What's one of the biggest mistakes investors make? Selling stocks too soon.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 55,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today